Loss of Reprimo and S100A2 expression in human gastric adenocarcinoma

Diagnostic Cytopathology

Volumn 39, Issue 10, 2011, Pages 752-757

  Luo, Jun ^a   Zhu, Youqing ^a   Yang, Guifang ^a   Gong, Lingling ^a   Wang, Bicheng ^a   Liu, Huan ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

gastric adenocarcinomas; Reprimo; S100A2

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INVASION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GASTRECTOMY; GENE EXPRESSION; GENE LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REPRIMO GENE; S100A2 GENE; STOMACH ADENOCARCINOMA; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CHEMOTACTIC FACTORS; FEMALE; GASTRECTOMY; GASTRIC MUCOSA; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; S100 PROTEINS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80052883098     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21461     Document Type: Article

References (34)

1. Tahara E,. Molecular mechanism of stomach carcinogenesis. J Cancer Res Clin Oncol 1993; 119: 265-272. (Pubitemid 23055428)
2. Tamura G,. Genetic and epigenetic alterations of tumor suppressor and tumor-related genes in gastric cancer. Histol Histopathol 2002; 17: 323-329. (Pubitemid 34116433)
3. Tang H, Hokita S, Che X, et al. Comparison of p53 expression in proximal and distal gastric cancer: Histopathologic correlation and prognostic significance. Ann Surg Oncol 1997; 4: 470-474. (Pubitemid 127725219)
4. Niimi C, Goto H, Ohmiya N, et al. Usefulness of p53 and Ki-67 immunohistochemical analysis for preoperative diagnosis of extremely well-differentiated gastric adenocarcinoma. Am J Clin Pathol 2002; 118: 683-692. (Pubitemid 37046312)
5. Matsubara D, Niki T, Ishikawa S, et al. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: Clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci 2005; 96: 844-857. (Pubitemid 43056122)
6. Ohki R, Nemoto J, Murasawa H, et al. Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J Biol Chem 2000; 275: 22627-22630. (Pubitemid 30646143)
7. Zhang Z, Li J, Lantry LE, et al. p53 transgenic mice are highly susceptible to 1,2-dimethylhydrazine-induced uterine sarcomas. Cancer Res 2002; 62: 3024-3029. (Pubitemid 34602389)
8. Santamaria-Kisiel L, Rintala-Dempsey AC, Shaw GS,. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 2006; 396: 201-214. (Pubitemid 43837235)
9. Heizmann CW, Fritz G, Schafer BW,. S100 proteins: Structure, functions and pathology. Front Biosci 2002; 7: d1356-d1368.
10. Tan M, Heizmann CW, Guan K, Schafer BW, Sun Y,. Transcriptional activation of the human S100A2 promoter by wild-type p53. FEBS Lett 1999; 445: 265-268. (Pubitemid 29117224)
11. Craig RW, Jabs EW, Zhou P, et al. Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: MCL1 maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease. Genomics 1994; 23: 457-463. (Pubitemid 24308268)
12. Lee SW, Tomasetto C, Sager R,. Positive selection of candidate tumor-suppressor genes by subtractive hybridization. Proc Natl Acad Sci USA 1991; 88: 2825-2829. (Pubitemid 21916512)
13. Sun Y,. Identification and characterization of genes responsive to apoptosis: Application of DNA chip technology and mRNA differential display. Histol Histopathol 2000; 15: 1271-1284.
14. Feng G, Xu X, Youssef EM, Lotan R,. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. Cancer Res 2001; 61: 7999-8004. (Pubitemid 33049393)
15. Hamilton JP, Sato F, Jin Z, et al. Reprimo methylation is a potential biomarker of Barrett's-associated esophageal neoplastic progression. Clin Cancer Res 2006; 12: 6637-6642. (Pubitemid 44876831)
16. Bernal C, Aguayo F, Villarroel C, et al. Reprimo as a potential biomarker for early detection in gastric cancer. Clin Cancer Res 2008; 14: 6264-6269.
17. Sato N, Fukushima N, Matsubayashi H, Iacobuzio-Donahue CA, Yeo CJ, Goggins M,. Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. Cancer 2006; 107: 251-257. (Pubitemid 44036553)
18. Suzuki M, Shigematsu H, Shivapurkar N, et al. Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. Cancer Lett 2006; 242: 222-230. (Pubitemid 44485305)
19. Suzuki M, Shigematsu H, Takahashi T, et al. Aberrant methylation of Reprimo in lung cancer. Lung Cancer 2005; 47: 309-314. (Pubitemid 40248735)
20. Hamilton JP, Sato F, Greenwald BD, et al. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol 2006; 4: 701-708. (Pubitemid 43825806)
21. Takahashi T, Suzuki M, Shigematsu H, et al. Aberrant methylation of Reprimo in human malignancies. Int J Cancer 2005; 115: 503-510. (Pubitemid 40656706)
22. Hirohashi S, Sugimura T,. Genetic alterations in human gastric cancer. Cancer Cells 1991; 3: 49-52.
23. Wicki R, Franz C, Scholl FA, Heizmann CW, Schafer BW,. Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation. Cell Calcium 1997; 22: 243-254. (Pubitemid 27490305)
24. Maelandsmo GM, Florenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O,. Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer 1997; 74: 464-469. (Pubitemid 27400171)
25. Ji J, Zhao L, Wang X, et al. Differential expression of S100 gene family in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2004; 130: 480-486. (Pubitemid 39119292)
26. Zhang X, Hunt JL, Shin DM, Chen ZG,. Down-regulation of S100A2 in lymph node metastases of head and neck cancer. Head Neck 2007; 29: 236-243. (Pubitemid 46339320)
27. Matsumoto K, Irie A, Satoh T, et al. Expression of S100A2 and S100A4 predicts for disease progression and patient survival in bladder cancer. Urology 2007; 70: 602-607. (Pubitemid 47464477)
28. Kyriazanos ID, Tachibana M, Dhar DK, et al. Expression and prognostic significance of S100A2 protein in squamous cell carcinoma of the esophagus. Oncol Rep 2002; 9: 503-510.
29. Lauriola L, Michetti F, Maggiano N, et al. Prognostic significance of the Ca(2+) binding protein S100A2 in laryngeal squamous-cell carcinoma. Int J Cancer 2000; 89: 345-349. (Pubitemid 30620287)
30. Diederichs S, Bulk E, Steffen B, et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 2004; 64: 5564-5569. (Pubitemid 39095550)
31. Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ,. Coordinately up-regulated genes in ovarian cancer. Cancer Res 2001; 61: 3869-3876. (Pubitemid 32720943)
32. Imazawa M, Hibi K, Fujitake S, et al. S100A2 overexpression is frequently observed in esophageal squamous cell carcinoma. Anticancer Res 2005; 25: 1247-1250. (Pubitemid 40546797)
33. El-Rifai W, Moskaluk CA, Abdrabbo MK, et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 2002; 62: 6823-6826. (Pubitemid 35424067)
34. Jin SP, Kim JH, Kim MA, et al. Prognostic significance of loss of c-fos protein in gastric carcinoma. Pathol Oncol Res 2007; 13: 284-289. (Pubitemid 351287308)